Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhopal, India.
CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
Pharmacogenomics J. 2024 Mar 15;24(2):9. doi: 10.1038/s41397-024-00326-1.
Adverse drug reactions (ADRs) are a significant public health concern and a leading cause of hospitalization; they are estimated to be the fourth leading cause of death and increasing healthcare costs worldwide. Carrying a genetic variant could alter the efficacy and increase the risk of ADRs associated with a drug in a target population for commonly prescribed drugs. The use of pre-emptive pharmacogenetic/omic (PGx) testing can improve drug therapeutic efficacy, safety, and compliance by guiding the selection of drugs and/or dosages. In the present narrative review, we examined the current evidence of pre-emptive PGx testing-based treatment for the prevention of ADRs incidence and hospitalization or emergency department visits due to serious ADRs, thus improving patient safety. We then shared our perspective on the importance of preemptive PGx testing in clinical practice for the safe use of medicines and decreasing healthcare costs.
药物不良反应（ADR）是一个重大的公共卫生关注点，也是导致住院的主要原因；据估计，ADR 是全球导致死亡的第四大原因，并增加了医疗保健成本。携带遗传变异可能会改变药物在目标人群中的疗效，并增加与常用药物相关的 ADR 风险。预防性药物基因组学/组学（PGx）检测的使用可以通过指导药物和/或剂量的选择来提高药物治疗的疗效、安全性和顺应性。在本叙述性综述中，我们检查了基于预防性 PGx 检测的治疗方法预防 ADR 发生率和因严重 ADR 而住院或急诊就诊的现有证据，从而提高了患者的安全性。然后，我们分享了我们对预防性 PGx 检测在临床实践中的重要性的看法，以确保安全用药并降低医疗保健成本。
